Cullinan Therapeutics Inc (NAS:CGEM)
$ 23.49 0.71 (3.12%) Market Cap: 1.35 Bil Enterprise Value: 883.64 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 36/100

Cullinan Oncology Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 06:25PM GMT
Release Date Price: $12.48 (+2.13%)
Unidentified Analyst

Good morning. Thank you for attending the conference. Thank you, Jeff, for being here. Pleased to present our next speaker, Jeff, CFO of Cullinan Oncology, ticker CGEM, oncology focused. We'll see, I think, and hear more about some of the exciting and broad pipeline that they have and their strategic focus in this field. And so with that, I'll just pass to you, Jeff.

Jeffrey Trigilio
Cullinan Oncology, Inc. - CFO & Treasurer

Thanks a lot, Eric. Appreciate it. So just before we begin, a quick note, what we're talking about today, we will have forward-looking statements. Investing in our securities involves risks. I would advise you to please consult with our 10-K and 10-Q to get a better understanding of the risk factors.

So yes, let me just pick up where Eric left off. So Cullinan Oncology, what are we all about?

First and foremost, we like to find high-impact targets in oncology. What do we mean by high impact? A target that's either involved in tumor cell proliferation and survival or targets that can really engender and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot